Following Syngenta and ChemChina making minor concessions to EU regulators recently, reports say the US$43 billion merger is on track to be approved in Europe.
The two agricultural giants made small concessions to allay concerns that this deal could hamper competition in the European market.
The deal has already been given the green light from a US national security panel, which removed a significant hurdle as critics had expressed concerns about a Chinese state-owned company becoming a major player in the US food chain.
It has also received the backing from Australian regulators, but is still being investigated by the European Commission amid concerns a merger could reduce competition in the market and impact on costs for farmers.
The Commission’s preliminary concern is that Syngenta and ChemChina each have strong partially overlapping portfolios of crops protection products such as herbicides, insecticides, fungicides and plant growth regulators.
Full Content: Financial Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Veteran Lawyers Launch Boutique Antitrust Firm in NY and DC
Oct 6, 2024 by
CPI
EU’s Top Court Upholds Antitrust Veto on Thyssenkrupp-Tata Steel Deal
Oct 6, 2024 by
CPI
Brazil’s Court Delays X’s Return Over Fine Payment Dispute
Oct 6, 2024 by
CPI
Tencent and Guillemot Family Consider Potential Buyout of Ubisoft
Oct 6, 2024 by
CPI
Second Price-Fixing Case Against Hotel-Casinos Dismissed by Federal Judge
Oct 6, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Refusal to Deal
Sep 27, 2024 by
CPI
Antitrust’s Refusal-to-Deal Doctrine: The Emperor Has No Clothes
Sep 27, 2024 by
Erik Hovenkamp
Why All Antitrust Claims are Refusal to Deal Claims and What that Means for Policy
Sep 27, 2024 by
Ramsi Woodcock
The Aspen Misadventure
Sep 27, 2024 by
Roger Blair & Holly P. Stidham
Refusal to Deal in Antitrust Law: Evolving Jurisprudence and Business Justifications in the Align Technology Case
Sep 27, 2024 by
Timothy Hsieh